NEW YORK, May 27, 2026, 09:02 EDT
enVVeno Medical Corp. shares were last available at $11.25 before regular Nasdaq trading on Wednesday, up 18 cents from the prior close, giving the Irvine, California-based medical-device developer a market value of about $7.4 million. It is a small stock, so a modest price move can carry more noise than signal.
The timing matters. Nasdaq’s regular market runs from 9:30 a.m. to 4 p.m. Eastern, and U.S. equity markets had just come through Monday’s Memorial Day closure; Wednesday was set up as a normal trading day, not a holiday tape.
The live issue is the company’s FDA-cleared path into the TAVVE U.S. pivotal study of enVVe, its non-surgical replacement venous valve. A pivotal study is a late-stage trial meant to support a regulatory approval case; an IDE, or investigational device exemption, is FDA permission for an investigational device to be used in a clinical study to collect safety and effectiveness data.
enVVeno’s latest quarterly filing shows why traders have narrowed in on that one catalyst. The company said the first stage of TAVVE is expected to start later this year with 10 patients, whose 30-day safety results will go to the FDA; the second stage would enroll 220 patients, with 165 receiving enVVe and 55 getting standard-of-care treatment, meaning the usual care used for comparison.
That is also the company’s reset. The filing said enVVeno first developed VenoValve, a surgical replacement venous valve, but received a not-approvable FDA letter for that product in August 2025 and is now focused on enVVe.
Cash gives the company room, though not much slack. enVVeno said this month it had $24.9 million in cash and investments at March 31, down from $28.2 million at year-end, and said those funds should support operations into the third quarter of 2027; Chief Executive Robert Berman pointed to a “strong balance sheet” and a “clearly defined regulatory pathway.” enVVeno Medical Corporation
The broader tape was firmer before the open. The SPDR S&P Biotech ETF was up about 1.3% in the latest available quote, while the iShares Russell 2000 ETF was up about 1.9%, a helpful backdrop for small healthcare names even if enVVeno’s own trial schedule is the bigger driver.
Competitive context is narrow, not empty. ClinicalTrials.gov lists a Cook Venous Valve System study for chronic venous insufficiency, while enVVeno’s annual report says the medical-device industry is highly competitive and can shift quickly as new products or techniques emerge.
Coverage is thin. enVVeno’s investor-relations page lists Jeffrey S. Cohen of Ladenburg Thalmann & Co. as covering the stock, and also states that both VenoValve and enVVe are investigational devices that are not approved or cleared for any indication in any market.
But the downside case is plain. The first safety cohort could disappoint, patient enrollment could drag, or trial spending could climb faster than planned; with no approved product and a sub-$10 million market value, the stock remains exposed to regulatory timing, financing risk and low-volume swings.
For now, the price story is a waiting game. enVVeno has a cleared study path and enough cash by its own account to reach several milestones, but the market is likely to treat the first TAVVE enrollment and 30-day safety readout as the next real test.
